Results 301 to 310 of about 126,024 (329)

New knowledge of the mechanisms of sorafenib resistance in liver cancer

Acta Pharmacologica Sinica, 2017
Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the treatment of advanced renal cell carcinoma in 2006, and as a unique target drug for
Hong-Yang Wang
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial.

JAMA Oncology
Importance Most patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy. Objective To determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally ...
Laura A. Dawson, Kathryn Winter, Jennifer J. Knox, A. X. Zhu, Sunil Krishnan, Chandan Guha, L. Kachnic, Michael Gillin, Theodore S. Hong, Timothy D Craig, Terence M Williams, Ali Hosni, Eric X. Chen, A. M. Noonan, Eugene J. Koay, Rishi Sinha, M. Lock, N. Ohri, J. Dorth, G. Delouya, A. Swaminath, J. Moughan, C. H. Crane   +22 more
semanticscholar   +1 more source

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

Nature Communications, 2019
Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common. By using genome-wide CRISPR/Cas9 library screening, we identify phosphoglycerate dehydrogenase (PHGDH), the first ...
Irene Oi-lin Ng, Chun-Ming Wong
exaly   +2 more sources

Sorafenib

DMW - Deutsche Medizinische Wochenschrift, 2010
A, Hansen, T, Eschenhagen
  +7 more sources

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

Journal of Clinical Oncology, 2018
Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver.
P. Chow, M. Gandhi, S. Tan, M. Khin, Ariunaa Khasbazar, J. Ong, S. Choo, P. Cheow, C. Chotipanich, K. Lim, L. Lesmana, T. Manuaba, B. Yoong, Aloysius Raj, C. S. Law, I. Cua, R. R. Lobo, C. Teh, Y. Kim, Yun Won Jong, Ho-Seong Han, S. Bae, H. Yoon, R. Lee, C. Hung, Cheng Peng, Po‐Chin Liang, A. Bartlett, K. Kok, C. Thng, A. Low, A. Goh, K. Tay, R. Lo, B. Goh, D. Ng, Ganesh Lekurwale, Wei Ming Liew, V. Gebski, K. Mak, K. Soo   +40 more
semanticscholar   +1 more source

Sorafenib

Reactions Weekly, 2021
  +7 more sources

Sorafenib

Reactions Weekly, 2013
  +7 more sources

Sorafenib

Reactions Weekly, 2016
  +5 more sources

Sorafenib

Reactions Weekly, 2017
  +5 more sources

Broadening horizons: the role of ferroptosis in cancer

Nature Reviews Clinical Oncology, 2021
Xin Chen, Rui Kang, Guido Kroemer
exaly